Study guide
5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment
Board Certified Specialist in Renal Nutrition CSR
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Kidney Disease Foundations
1.1 CDR CSR Exam Structure, Eligibility, Logistics & the 2023 Content Outline 1.2 Renal Anatomy, Physiology & Glomerular Hemodynamics 1.3 CKD Etiology, KDIGO Staging & Progression Risk
2 Chapter 2: Domain 1 — Anthropometric & Body Composition Assessment
2.1 Dry Weight Determination, Fluid Assessment & Interdialytic Weight Gain 2.2 Anthropometric Measurement Standards (Knee Height, Skinfolds, Frame Size) 2.3 Body Composition Analysis: BIA, BIS, DXA & Handgrip Dynamometry
3 Chapter 3: Domain 1 — Nutrition-Focused Physical Findings & PEW Assessment Tools
3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology 3.2 Subjective Global Assessment (7-Point SGA) in Dialysis 3.3 Malnutrition Inflammation Score (MIS) & Scoring Protocols 3.4 Nutrition-Focused Physical Exam (NFPE) for Muscle & Fat Loss
4 Chapter 4: Domain 1 — Diet, Medical, Medication & Psychosocial History
4.1 Dietary Intake Assessment & Food Frequency Methods in CKD 4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements 4.3 Psychosocial, Social & Functional History in Renal Nutrition Assessment
5 Chapter 5: Domain 1 — Medical Tests & Procedures by Treatment Modality
5.1 Hemodialysis Clinical Assessment & Vascular Access Considerations 5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment 5.3 AKI, CRRT & Pediatric Renal Disease Assessment
6 Chapter 6: Domain 1 — Nutrition Diagnosis: Terminology, Etiology & Reasoning
6.1 Standardized Nutrition Diagnostic Terminology (NCP) in Nephrology 6.2 Etiology & Root-Cause Analysis for Renal Nutrition Problems 6.3 Diagnostic Reasoning for Fluid, Mineral & Protein Imbalances
7 Chapter 7: Domain 1 — Nutrition Diagnosis in Complex Patients
7.1 Formulating Valid PES Statements in Complex Dialysis Patients 7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD 7.3 Diagnostic Prioritization across Cardiorenal & Diabetic Nephropathy
8 Chapter 8: Domain 2 — Food & Nutrient Delivery: Protein & Energy
8.1 KDOQI 2020 Protein Targets: Non-Dialysis CKD (LPD vs. VLPD) 8.2 Protein Prescriptions for Hemodialysis and Peritoneal Dialysis 8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)
9 Chapter 9: Domain 2 — Electrolytes, Fluid, Acid–Base & Micronutrients
9.1 Potassium Management: Dietary Restriction, Leaching & K-Binders 9.2 Sodium & Fluid Prescriptions across Dialysis Modalities 9.3 Acid-Base Homeostasis & Bicarbonate Replacement Therapy 9.4 Micronutrient, Trace Mineral & Vitamin Supplementation in ESRD
10 Chapter 10: Domain 2 — Medications & Specialized Nutrition Support
10.1 CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics 10.2 Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs 10.3 Enteral, IDPN & Intraperitoneal Amino Acid Nutrition Support
11 Chapter 11: Domain 2 — Treatments Across the Continuum: Transplant & Comorbidities
11.1 Kidney Transplant I: Candidacy, Living Donors & the Early Post-Transplant Period 11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection 11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT 11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure
12 Chapter 12: Domain 2 — Monitoring & Evaluation: Labs, Fluid & Nutrition Trends
12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending 12.2 Monitoring Fluid Balance, Blood Pressure & Cardiovascular Risk 12.3 Longitudinal Assessment of Nutritional Status & Weight Trajectories
13 Chapter 13: Domain 2 — Monitoring Dialysis Adequacy & Kinetics
13.1 Hemodialysis Adequacy: Urea Kinetic Modeling, spKt/V & URR 13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET) 13.3 Normalized Protein Catabolic Rate (nPCR / nPNA) Interpretation 13.4 Troubleshooting Inadequate Dialysis vs. Dietary Non-Adherence
14 Chapter 14: Domain 2 — Care Coordination, Communication & Education
14.1 Interdisciplinary Team Care, Patient Education & Counseling Ethics 14.2 Individualized & Group Education: Medicare MNT and KDE Benefits, Caregivers & Curricula 14.3 Interfacility Coordination of Care: Hospital Handoffs, Transfers, Transplant Centers & Modality Changes 14.4 Psychosocial Support & Resources: Food Assistance, Financial Programs, Rehabilitation & Peer Support
15 Chapter 15: Domain 3 — Regulations & Quality Management
15.1 CMS Conditions for Coverage: IDT, Dietitian Qualifications, Assessment & Plan-of-Care Timelines 15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program 15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool
16 Chapter 16: Domain 3 — Evidence-Based Practice: Guidelines, Research & Protocols
16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements 16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI 16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials 16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways
5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment
Key Takeaways Explain This Topic AI
Peritoneal membrane transport follows the three-pore model: large pores mediate continuous macromolecular protein losses (5–15 g/day), small pores facilitate small solute diffusion and convective clearance, and ultrasmall aquaporin-1 pores handle free water transport and sodium sieving.
Transperitoneal dextrose absorption is substantial (60% to 70% in CAPD, 40% to 50% in APD), delivering 300 to 800+ kcal daily of dextrose monohydrate (3.4 kcal/g), which frequently induces early satiety, hypertriglyceridemia, weight gain, and diabetic dysglycemia.
KDOQI 2020 recommends 1.0–1.2 g protein/kg/day for metabolically stable PD patients (the older KDOQI 2000 target was 1.2–1.3), individualized upward when effluent protein (5–15 g/day) and amino acid (2–4 g/day) losses are large.
Acute peritonitis markedly increases large-pore permeability, causing effluent protein losses to surge to 20 to 30+ g/day, commonly requiring temporary escalation of dietary protein intake to about 1.5 g/kg/day or more.
Icodextrin provides sustained colloid osmosis for long dwells without contributing dextrose calories, but its circulating maltose metabolite produces falsely elevated glucose readings on point-of-care GDH-PQQ glucometers, posing fatal hypoglycemia risks.
Last updated: September 2026
Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment
Peritoneal Dialysis (PD) utilizes the patient's living peritoneal membrane as a semipermeable bidirectional transport barrier. Solute clearance occurs between mesenteric capillary blood and hypertonic dialysate instilled into the peritoneal cavity. For the renal nutrition specialist, PD presents unique metabolic challenges: continuous transperitoneal absorption of dextrose creates a substantial caloric burden, while persistent peritoneal effluent protein and amino acid losses dramatically escalate dietary protein requirements.
Peritoneal Membrane Physiology: The Three-Pore Model
The universally accepted biophysical framework describing peritoneal transport is the Three-Pore Model formulated by Bengt Rippe. Transport kinetics across the capillary endothelium are governed by three anatomically and functionally distinct pore sizes: ┌────────────────────────────────────────────────────────────────────────┐
- │ Peritoneal Three-Pore Framework │
- ├────────────────────────────────────────────────────────────────────────┤
- │ 1. Large Pores (Radius: 20 – 40 nm) │
- │ • Represent < 0.01% of total pore area. │
- │ • Located at inter-endothelial gaps / post-capillary venules. │
- │ • Mediate macromolecular transport: serum albumin, immunoglobulins. │
- │ • Responsible for baseline effluent loss: 5–15 g protein/day. │
- │ │
- │ 2. Small Pores (Radius: 4.0 – 4.5 nm) │
- │ • Represent 90% – 95% of total pore surface area. │
- │ • Located between endothelial cell clefts. │
- │ • Mediate small solute clearance: urea, creatinine, Na+, K+, glucose. │
- │ • Primary pathway for small-molecule diffusion and convection. │
- │ │
- │ 3. Ultrasmall Pores / Aquaporin-1 (Radius: 0.25 – 0.4 nm) │
- │ • Represent 1% – 2% of total hydraulic conductance. │
- │ • Transcellular water channels (Aquaporin-1) exclusively for water. │
- │ • Mediate 40% – 50% of ultrafiltration during hypertonic dwells. │
- │ • Generate "Sodium Sieving" (transcellular water dilutes dialysate Na)│
- └────────────────────────────────────────────────────────────────────────┘
- The Sodium Sieving Phenomenon
During the initial 60 to 90 minutes of a hypertonic dextrose dwell, crystalloid osmosis drives transcellular water flux across ultrasmall aquaporin-1 channels into the peritoneal cavity. Because aquaporins reject solutes, pure water enters the dialysate without accompanying sodium. This process dilutes the dialysate sodium concentration below the baseline bath level (typically a fall of roughly 5–10 mEq/L in the first hour of a hypertonic 4.25% dwell), a diagnostic hallmark known as sodium sieving . Failure of dialysate sodium to dip indicates aquaporin dysfunction or loss of membrane ultrafiltration capacity.
Peritoneal Equilibration Test (PET) & Transporter Categorization
The standard 4-hour Peritoneal Equilibration Test (PET) using a 2.5% dextrose dwell categorizes patients into four transport phenotypes based on the dialysate-to-plasma creatinine ratio ( D / P c r D/P_{cr} D / P cr ) and dialysate glucose retention ( D / D 0 D/D_0 D / D 0 ):
High (Fast) Transporters ( D / P c r > 0.81 D/P_{cr} > 0.81 D / P cr > 0.81 ) : Rapid solute equilibrium. Glucose absorbs very rapidly, dissipating the osmotic gradient quickly. Patients achieve excellent small-solute clearance but suffer poor ultrafiltration on long dwells, absorbing massive dextrose calorie loads and losing high amounts of protein.
High-Average Transporters ( D / P c r = 0.65 – 0.81 D/P_{cr} = 0.65\text{--}0.81 D / P cr = 0.65 – 0.81 ) : Balanced solute clearance and ultrafiltration; well-suited for automated peritoneal dialysis (APD) or standard continuous ambulatory peritoneal dialysis (CAPD).
Low-Average Transporters ( D / P c r = 0.50 – 0.64 D/P_{cr} = 0.50\text{--}0.64 D / P cr = 0.50 – 0.64 ) : Slower equilibrium; excellent sustained ultrafiltration during long dwells; ideal for standard CAPD.
Low (Slow) Transporters ( D / P c r < 0.50 D/P_{cr} < 0.50 D / P cr < 0.50 ) : Sluggish solute clearance but robust sustained ultrafiltration; requires large exchange volumes or long dwells to achieve adequacy.
Peritoneal Dialysis Modalities
Continuous Ambulatory Peritoneal Dialysis (CAPD) : Manual, gravity-assisted exchanges performed 4 to 5 times daily. Each exchange dwells for 4 to 6 hours during daytime and 8 to 10 hours overnight. Solute removal is continuous and steady.
Automated Peritoneal Dialysis (APD / CCPD) : An automated mechanical cycler performs 3 to 6 rapid exchanges overnight over 8 to 10 hours while the patient sleeps. The cycler may leave the abdomen "dry" during the day or instill a long daytime manual or automated dwell ("wet day") to optimize solute clearance.
Transperitoneal Dextrose & Caloric Absorption Calculations
Commercial peritoneal dialysate utilizes dextrose monohydrate as the crystalloid osmotic agent to generate transmembrane hydrostatic and osmotic gradients.
Dextrose Solution Concentrations
Dialysate formulations are labeled by dextrose monohydrate concentration:
1.5% Solution : 1.5 g/dL = 15 g/L (anhydrous dextrose equivalent = 1.36% or 13.6 g/L).
2.5% Solution : 2.5 g/dL = 25 g/L (anhydrous dextrose equivalent = 2.27% or 22.7 g/L).
4.25% Solution : 4.25 g/dL = 42.5 g/L (anhydrous dextrose equivalent = 3.86% or 38.6 g/L).
Energy Value of Dextrose Monohydrate
Dextrose monohydrate yields 3.4 kcal per gram , distinguishing it from anhydrous glucose or dietary carbohydrates (4.0 kcal/g).
Dextrose Absorption Fraction ( F a b s F_{abs} F ab s )
The proportion of instilled dextrose absorbed across the peritoneal capillary bed depends on dwell duration and membrane transport category:
CAPD (Long Dwells, 4–8 hours) : Approximately 60% to 70% (mean ~65%) of instilled dextrose is absorbed into systemic circulation.
APD (Short Nighttime Dwells, 1–2 hours) : Approximately 40% to 50% (mean ~45%) of instilled dextrose is absorbed due to rapid cycling.
Mathematical Formulation for Caloric Absorption
To quantify total daily dialysate caloric contribution, the dietitian applies the following formula:
Daily Absorbed Dextrose (g) = ∑ [ Instilled Volume (L) × Dextrose Conc (g/L) × F a b s ] \text{Daily Absorbed Dextrose (g)} = \sum \left[ \text{Instilled Volume (L)} \times \text{Dextrose Conc (g/L)} \times F_{abs} \right] Daily Absorbed Dextrose (g) = ∑ [ Instilled Volume (L) × Dextrose Conc (g/L) × F ab s ]
Total Dialysate Calories (kcal/day) = Daily Absorbed Dextrose (g) × 3.4 kcal/g \text{Total Dialysate Calories (kcal/day)} = \text{Daily Absorbed Dextrose (g)} \times 3.4\text{ kcal/g} Total Dialysate Calories (kcal/day) = Daily Absorbed Dextrose (g) × 3.4 kcal/g
Worked Clinical Example
A CAPD patient uses three 2.0-liter bags of 2.5% dextrose and one 2.0-liter bag of 4.25% dextrose daily. Assuming an average absorption fraction of 65% ( 0.65 0.65 0.65 ):
Grams Dextrose Instilled :
Three 2.0 L bags of 2.5%: 3 × 2.0 L × 25 g/L = 150 g 3 \times 2.0\text{ L} \times 25\text{ g/L} = 150\text{ g} 3 × 2.0 L × 25 g/L = 150 g
One 2.0 L bag of 4.25%: 1 × 2.0 L × 42.5 g/L = 85 g 1 \times 2.0\text{ L} \times 42.5\text{ g/L} = 85\text{ g} 1 × 2.0 L × 42.5 g/L = 85 g
Total instilled dextrose: 150 g + 85 g = 235 g/day 150\text{ g} + 85\text{ g} = 235\text{ g/day} 150 g + 85 g = 235 g/day
Grams Dextrose Absorbed :
235 g × 0.65 = 152.75 g absorbed/day 235\text{ g} \times 0.65 = 152.75\text{ g absorbed/day} 235 g × 0.65 = 152.75 g absorbed/day
Caloric Contribution :
152.75 g × 3.4 kcal/g = 519.35 kcal/day 152.75\text{ g} \times 3.4\text{ kcal/g} = 519.35\text{ kcal/day} 152.75 g × 3.4 kcal/g = 519.35 kcal/day (~520 kcal/day).
Metabolic Consequences of Glucose Absorption
Absorbing 300 to 800+ kcal daily of transperitoneal dextrose induces profound metabolic alterations:
Appetite Suppression & Oral Anorexia : Transperitoneal glucose infusions suppress hunger signals, inducing early satiety. Patients consume insufficient dietary protein, leading to sarcopenia masked by fluid and fat gain.
Atherogenic Dyslipidemia : Continuous glucose influx promotes hepatic de novo lipogenesis, provoking marked hypertriglyceridemia (often > 400 – 800 > 400\text{--}800 > 400 – 800 mg/dL) and elevated small, dense LDL particles.
Weight Gain & Central Adiposity : Patients gain substantial adipose tissue, particularly visceral fat, accelerating metabolic syndrome.
Worsening Glycemic Control : In diabetic individuals, continuous glucose absorption causes refractory hyperglycemia, frequently necessitating intraperitoneal (IP) insulin regimens.
Alternative Osmotic Agents: Icodextrin
Icodextrin is a 7.5% solution containing high-molecular-weight glucose polymers derived from corn starch. Unlike dextrose, which generates crystalloid osmosis, icodextrin functions via colloid osmosis , exerting sustained oncotic pressure across small endothelial pores over long dwell intervals (8 to 16 hours). It is exceptionally effective for the long daytime dwell in APD or overnight dwell in CAPD.
Caloric and Fluid Advantages
Because icodextrin is a large polymer, it is absorbed very slowly via the peritoneal lymphatics rather than capillaries. It does not contribute significant dextrose calories, blunts hyperinsulinemia, and preserves ultrafiltration in fast transporters.
Fatal Laboratory Interference: GDH-PQQ Glucometer Alert
Critical Safety Warning : Absorbed icodextrin is metabolized by circulating alpha-amylase into maltose, maltotriose, and maltotetraose. Circulating maltose cross-reacts with point-of-care capillary glucometers using glucose dehydrogenase pyrroloquinoline quinone (GDH-PQQ) or glucose-dye-oxidoreductase testing methods .
The glucometer misinterprets maltose as glucose, displaying falsely elevated blood glucose readings (often > 300–400 mg/dL) . If patients or unaware clinicians administer corrective rapid-acting insulin, catastrophic, fatal neuroglycopenic hypoglycemia ensues. Patients prescribed icodextrin must exclusively utilize glucose-specific monitors incorporating glucose oxidase (GOD) or glucose dehydrogenase flavin-adenine dinucleotide (GDH-FAD) .
Peritoneal Protein & Amino Acid Effluent Losses
Unlike hemodialysis where the intact dialyzer membrane prevents intact protein leakage, the large pores of the peritoneal capillary bed allow continuous passive transudation of macromolecules into the dialysate.
- Clinical Parameter Baseline Stable Peritoneal Dialysis Acute Peritonitis Episode
- Daily Effluent Protein Loss 5 – 15 g/day (60–70% albumin) 20 – 30+ g/day (surging 2- to 3-fold)
- Daily Effluent Amino Acid Loss 2 – 4 g/day 4 – 8 g/day
Recommended Dietary Protein Target 1.0 – 1.2 g/kg/day (KDOQI 2020; individualize upward for large losses) Commonly ≥ 1.5 g/kg/day
Peritonitis-Induced Protein Hypercatabolism
Acute bacterial peritonitis induces severe peritoneal vasodilation and inflammatory widening of endothelial large pores. Daily effluent protein losses surge from 5–15 g/day to 20 to 30+ g/day , persisting for several weeks following clinical resolution of infection. This acute macromolecular drain rapidly precipitates refractory hypoalbuminemia ( < 3.0 < 3.0 < 3.0 g/dL), peripheral edema, and muscle wasting. The renal dietitian must aggressively increase protein intake to 1.5–2.0 g/kg/day, utilizing high-biological-value modular protein supplements to prevent fatal protein-energy wasting.